GLMD - CONSENSUS CO - Galmed Pharmaceuticals

The speculative potential of Galmed Pharmaceuticals (GLMD) is based on drug delivery patents, although the lack of sales weakens the firm's position. The project's success depends on the safety of NASH therapy and the search for a distributor. The share price visualized below, recorded at 96.13, accompanies the Israeli biotech, which is burning capital on liver research without operating revenue or positive cash flow.

Galmed Pharmaceuticals utilizes a flexible business model with outsourced manufacturing to minimize capital expenditures, focusing value on intellectual property. This specific structure is reflected in the average target price calculations from leading analysts, who are recalibrating DCF models to align with current market conditions, thereby determining the asset's fair value through the current consensus target.